Keyword
in
Collection
Date
to
Houston Voice, No. 903, February 13, 1998
File 009
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 903, February 13, 1998 - File 009. 1998-02-13. University of Houston Libraries. University of Houston Digital Library. Web. February 21, 2020. https://digital.lib.uh.edu/collection/montrose/item/1305/show/1276.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(1998-02-13). Houston Voice, No. 903, February 13, 1998 - File 009. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/1305/show/1276

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 903, February 13, 1998 - File 009, 1998-02-13, Montrose Voice, University of Houston Libraries, accessed February 21, 2020, https://digital.lib.uh.edu/collection/montrose/item/1305/show/1276.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 903, February 13, 1998
Contributor
  • Michelak, J. C.
  • Murphy, Terry
Publisher Window Media
Date February 13, 1998
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 009
Transcript BTG PHARMACEUTICALS OXANDRIN3 oxandrolone tablets Revised. May 1996 tS DESCRIPTION Oxandrin" oral tablets contain 2 5 mg ol the anabolic steroid oxandrolone Oxandrolone is 17|l-hydroxy-l7*(-methyl-2-oxa-5a- androslan-3-one Inactive ingredients include cornstarch, lactose, magnesium siearale. and hydroxypropyl melhylcellulose CLINICAL PHARMACOLOGY Cerlain clinical eflects and adverse reac androgenic properties ol litis class of drugs. Compute dissociation ol anabolic and androgenic eflects has nol been achieved The actions ol anabolic steroids are therefore similar to those ol wrth and sexual development it given lo young children. Anabolic steroids suppress the gonadotropic functions ol lhe pHurtary and may exert a direct elfecl jpon the lestes. During exogenous administration of anabolic androgens, endogenous lestosterone release is inhibited through inhibition ol ptluitary luteinizing hormone (LH) Al large doses, spermatogenesis may Be suppressed through feedback inhibition ol pituitary follicle-stimulating hormone (FSH) Anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. These levels revert lo normal on discontinuation ot Ireatmenl INDICATIONS AND USAGE Oxandrin is indicated as adjunctive therapy to promote weight gam alter weight loss following extensive surgery, chronic infections, or severe trauma, and in some palients who without deli- nite pathophysiologic reasons fait to gain or to maintain normal weight, le offset the protein calabolism associated with prolonged administration ol corticosteroids, and lor Ihe relief of the bone pain frequently accompanying osteoporosis (See DOSAGE AND ADMINISTRATION) DRUG ABUSE AND DEPENDENCE Oxandrolone is dassllied as a controlled substance under the Anabolic Steroids Control Act ol 1990 and has been assigned lo Schedule III (non-narcotic) CONTRAINDICATIONS 1. Known or suspected carcinoma ot lhe prostate or the 3 Pregnancy. Because ol possible masculiniiation ol the lelus Oxandnn has been shown to cause embryotox icily, letotoxicity. infertility, and masculmudlion oi lemale animal oltspnng when given in doses 9 limes the human 4 Nephrosis, lhe nephrotic phase ol nephritis 5. Hypercalcemia WARNINGS PEL/OS'S HEPATIS. A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS. HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION. BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER FAILURE THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING LIVER FAILURE OR INTRAABDOMINAL HEMORRHAGE DEVELOPS WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS LIVER CELL TUMORS ARE ALSO REPORTED MOST OFTEN THESE TUMORS ARE BENIGN AND ANDRO- GEN-DEPENDENT. BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR HOWEVER. HEPATIC TUMORS ASSOCIATED WITH ANDROGENS OH ANABOLIC STEROIDS ARE MUCH MORE VASCULAR THAN OTHER HEPATIC TUMORS AND MAY BE SILENT UNTIL LIFE-THREATENING INTRA-ABDOMINAL HEMOR RHACE DEVELOPS BLOOD LIPID CHANGES THAT ABE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF ATHEROSCLEROSIS ARE SEEN IN PATIENTS TREATED WITH ANDROGENS OR ANABOLIC STEROIDS. THESE CHANGES INCLUDE DECREASED HIGH-DENSITY LIPOPROTEINS AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEINS THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE Cholestatic hepatitis and jaundice may occur with 17-alpha- alkylated androgens al a relatively low dose If cholestalic hepatitis with jaundice appears or if liver function tests Become abnormal, oxandrolone should be discontinued and fhe etiology should be determined. Drug-induced jaundice is reversible when In patients with Breasl cancer, anabolic steroid therapy may cause hypercalcemia by stimulating osteolysis. Oxandrolone therapy should Be discontinued if hypercalcemia occurs. Edema wilh or without congestive head failure may be a serious complication in patienis with preexisting cardiac, renal, or hepatic disease. Concomitant adminislration ol adrenal cortical steroid or ACTH may increase the edema In children, androgen therapy may accelerate Bone maturation wilhoul producing compensatory gam in linear growth. This adverse effect results in compromisea aduH height The younger Ihe child, the greater the risk ol compromising final mature height The effect on Bone maturation should be monitored By assessing Bone age ot Ihe tell wrist and hand every 6 months i See PRECAUTIONS: Laboratory tests) Geriatric patienis trealed wilh androgenic anabolic sleroids may be al an increased risk for the development ol prostatic hypertrophy and prostatic carcinoma. ANABOLIC STEROIDS HAVE NOT BEEN SHOWN TO ENHANCE ATHLETIC ABILITY. PRECAUTIONS Women should be observed lor signs ol viriWalion (deepening ol the voice, hirsutism, acne, clitoromegaly). Discontinualion ol drug therapy at the time of evidence ol mild virilism is necessary to prevenl irreversible virilization Some virilizing changes in therapy and are nol prevented by concomitant use ol estrogens. Menstrual irregularities may also occur. Anabolic sleroids may cause suppression ol dotting factors II. V, VII, and X, and an increase in prothrombin time. Information lor patient*: The physician should instruct patienis to report any ol Ihe following side eftects ol androgens: Males: Too frequenf or persisleni erections of Ihe penis. appearance or aggravation ol acne. I, changes in menstrual periods. All palients: Nausea, vomiting, changes in skin color, or ankle h'Cw quent determination ot urine and serum calcium levels during the course ol therapy (See WARNINGS) Because of the hepatotoxicity associated with Ihe use of 17- alpha-alkylated androgens, liver function tests should be obtained periodically. Periodic (every 6 months) x-ray examinations ol bone age should be mate during treatment ol children ti the epiphyseal centers. Serum lipids and high-density lipoprotein cholesterol determinations should be done periodically as androgenic anabolic steroids have been reported to increase low-densily lipoproteins. Serum cholesterol levels may increase during therapy Therefore, caution is required when administering these agents to palients with a history ol myocardial infarction or coronary artery disease Serial determinations of serum cholesterol should be made and therapy adiusted accordingly Hemoglobin and hematocrit should be checked periodically lor polycythemia in palients who are receiving high doses ol ana- D| goi t'yiK-qlytornic Anabolic sleroids may increase sensitivity to oral antKoagulants Dosage of the anticoagulant may have lo be decreased in order lo maintain desired prothrombin time Patients receiving oral anb- coagulanl therapy require close monitoring, especially when anabolic sleroids are started or stopped Oral hypoglycemic agents: Oxandrolone may inhibit lh< Adrenal steroids or ACTH: In patients with edema, conr*omrtant administration with adrenal cortical steroids or ACTH may increase the edema Drugtaboralory test interactions: Anabolic steroids may decrease levels ol thyroxine-binding globulin, resulting in decreased total T, serum levels and increased resin uptake ol T3 and T,. Free thyroid hormone levels remain unchanged In addition, a decrease m PBi and radioactive iodine uptake may occur Carcinogenesis, mutagenesis, impairment ol fertility Oxandrolone has not been tested in laboratory ami cmogenic or mutagenic effecis In 2-year chrome I ies. a dose-related reduction ol speri organ weights (testes, prostate, uterus, adrenals, and pituitary) wen Liver cell tumors have been reported in patients receiving long- term therapy with androgenic anabolic steroids in high doses (See WARNINGS) Withdrawal ol the drugs did not lead to regression ol Ihe tumors in al cases. Geriatric patients trealed wilh androgenic anabolic sleroids may be al an increased risk tor the development ot proslalic hypertrophy and prostatic carcinoma. milk Because of the potential ol senous adverse reactions in nursing mtanis Irom oxandrolone. a decision should be made whether to discontinue nuising oi lo discontinue the drug, taking into account the importance ol the drug to the mother Pediatric use: Anabolic agents may accelerate epiphyseal maturation more rapidly than linear growth in children and the effect may continue lor 6 months alter the drug has been stopped Therefore, therapy should be moniiored by x-ray studies at 6-rnonlh intervals in order to avoid the risk ol compromising adult heighl Androgenic anabolic steroid therapy should be usasd very cautiously in children and only by specialists who are aware ol the etfects on bone maturation (See WARNINGS) ADVERSE REACTIONS The following adverse reactions have been associated with use ot anabolic steroids: Hepatic: Cholestatic laundice with, rarely, hepalic necrosis and death Hepatocellular neoplasms and poliosis hepatis with long- term therapy (See WARNINGS) Reversible changes in liver function tests also occur including increased bromsulfophihatom (BSP) reiention, and increases in serum bilirubin, aspartate aminotransferase (AST, SGOT) and aid Prepubertal: Phalhc enlargement and increased frequency or PostptJMHlal IrJutHtioii ol testicular lunclion. ti and oligospermia, impotence, chronic priapis and bladder imiability Hematologic. Bleeding in pi ...,.„;l.r: Breasl: Gynecomastia Larynx Deepening of the voice in females. Hair. Hirsutism and male pattern baldness in females. Skin: Acne (especially in females and prepubertal males). Skeletal: Premature closure of epiphyses in children (See PRECAUTIONS: Pediatric use) Fluid and electrotyles Edema, retention of serum electrolytes (sodium chloride, potassium, phosphale, calcium) Metabolic/Endocrine: Decreased glucose tolerance (See PRECAUTIONS: Laboratory tests), increased creatinine excretion, increased serum levels ot creatinine phosphoklnase (CPK) Masculinr-ration ol the lelus Inhibition ol gonadotropin secretion No symptoms or signs OVERDOSAGE is known, but gaslhc lavage DOSAGE ANO ADMINISTRATION Therapy with anabolic steroids is adjunctive to and not a replace men! lor conventional therapy. The duration of therapy wilh Oxandrin (oxandrolone) will depend on Ihe response ol the patient and Ihe possible appearance ol adverse reactions. Therapy should be intermittent *4oUtts:The usual adult dosage ol Oxandrin is one 2 5-mg tablet 2 to 4 times daitv However, the response ol indMduals lo ana- o< as title as 2.5 mg or B 2(1 m if therapy ol 2 lo 4 response. / adequate. This may tn Children: For cnildren the total daily dosage ol Oxandrin is SO.! mg per kilogram body weight or - o 045 mg per pound of body we#it. This may be repeated intermittently as indfoaled d scored with BTG >t the scoredne on the other side, bottles ol 100 (NDC 54396-1 11-11) Caution: Federal law prohibits dispensing without presenption Manufactured fee BTG Pharmaceuticals try: G.D Searle S Co. Chicago. IL 60680 Address mettcal inquiries fo BTG Pharmaceuticals Medical Attairs BTG PHARMACEUTICALS OIN960411-0401 BTG PHARMACEUTICALS OXANDRIN" oxandrolone tablets @
File Name uhlib_31485329_n903_008.jpg